0001209191-21-023139.txt : 20210325
0001209191-21-023139.hdr.sgml : 20210325
20210325213925
ACCESSION NUMBER: 0001209191-21-023139
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210325
FILED AS OF DATE: 20210325
DATE AS OF CHANGE: 20210325
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ORBIMED ADVISORS LLC
CENTRAL INDEX KEY: 0001055951
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40236
FILM NUMBER: 21774397
BUSINESS ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (212) 739-6400
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: OrbiMed Genesis GP LLC
CENTRAL INDEX KEY: 0001808744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40236
FILM NUMBER: 21774395
BUSINESS ADDRESS:
STREET 1: 601 LEXINGTON AVENUE, 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (212) 739-6400
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE, 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: OrbiMed Capital GP VI LLC
CENTRAL INDEX KEY: 0001682115
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40236
FILM NUMBER: 21774396
BUSINESS ADDRESS:
STREET 1: 601 LEXINGTON AVENUE, 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 212-739-6400
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE, 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Edgewise Therapeutics, Inc.
CENTRAL INDEX KEY: 0001710072
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 821725586
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O ORBIMED ADVISORS LLC
STREET 2: 601 LEXINGTON AVE, 54TH FLR.
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 212-739-6451
MAIL ADDRESS:
STREET 1: C/O ORBIMED ADVISORS LLC
STREET 2: 601 LEXINGTON AVE, 54TH FLR.
CITY: NEW YORK
STATE: NY
ZIP: 10022
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2021-03-25
0
0001710072
Edgewise Therapeutics, Inc.
EWTX
0001055951
ORBIMED ADVISORS LLC
601 LEXINGTON AVE., 54TH FLR.
NEW YORK
NY
10022
1
0
1
0
0001682115
OrbiMed Capital GP VI LLC
C/O ORBIMED ADVISORS LLC
601 LEXINGTON AVE., 54TH FLR.
NEW YORK
NY
10022
1
0
1
0
0001808744
OrbiMed Genesis GP LLC
C/O ORBIMED ADVISORS LLC
601 LEXINGTON AVE., 54TH FLR.
NEW YORK
NY
10022
1
0
1
0
Common Stock
316920
I
See Footnotes
Series A Preferred Stock
0.00
Common Stock
8187100
I
See Footnotes
Series B-1 Preferred Stock
0.00
Common Stock
1572960
I
See Footnotes
Series B-2 Preferred Stock
0.00
Common Stock
1301626
I
See Footnotes
Series C Preferred Stock
0.00
Common Stock
1668350
I
See Footnotes
Series C Preferred Stock
0.00
Common Stock
272724
I
See Footnotes
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationship, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI.
Immediately prior to the completion of the Issuer's initial public offering of Common Stock, each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series C Preferred Stock shall be exchanged at a 1:1 ratio for shares of Common Stock.
This report on Form 3 is jointly filed by OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC and OrbiMed Genesis GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Peter A. Thompson, an employee of OrbiMed Advisors LLC, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borbo and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis.
OrbiMed Advisors LLC By Douglas Coon, authorized signatory
2021-03-25
OrbiMed Capital GP VI LLC By Douglas Coon, authorized signatory
2021-03-25
OrbiMed Genesis GP LLC, By Douglas Coon, authorized signatory
2021-03-25